Minerva Neurosciences (NERV) in Focus: Stock Jumps 8.2% – Tale of the Tape

January 7, 2015 Technicals 0

Zacks

Minerva Neurosciences, Inc. (NERV) was a big mover last session, as the company saw its shares rise over 8% on the day. The increase came after the company announced positive results from a primate study on an analog of its Parkinson’s disease candidate. This resulted in solid volume with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 38.38% in the past one-month time frame.

None of the estimates for this medical drugs stock were revised over the past 60 days. The Zacks Consensus Estimate however moved higher over the same time frame, suggesting that more solid trading could be ahead for the stock. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Minerva Neurosciences currently carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

A better-ranked stock in the same industry is AcelRx Pharmaceuticals, Inc. (ACRX), carrying a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

Be the first to comment

Leave a Reply